I6
Lab On Card – Miniaturized ELISA on Microfluidic Chip
Josef Haščyn, Lab On Card; Dr Tomas Riedel, Lab On Card; Dr Andres de los Santos, Lab On Card; Dr Marek Škereň, IQS Group; Dr Zuzana Riedelova, Lab On Card; Dr Michal Pohludka, Lab On Card
Lab On Card s.r.o.
Challenge
Addressing the diagnostic needs of the 4.5 billion people worldwide who currently lack access to essential healthcare services, particularly in resource-limited settings where centralized laboratories are unavailable and timely diagnostic decisions are critical for effective disease management.
Technology
Leveraging the benefits of microfluidics and the well-established ELISA method together. Lower sample and reagent volumes, faster reaction time and high sensitivity and specificity. Providing a new rapid and reliable Point-of-Care solution from a single drop of blood. We combine biotech and micro and nanostructuring expertise with an in-house facility for a scale-up manufacturing.
Commercial Opportunity
Lab On Card initially targets the global Point-of-Care (PoC) infectious disease diagnostics market, which is estimated to be valued at several billion USD today and projected to grow significantly over the next decade. For example, the global PoC infectious disease testing market is forecast to grow to nearly USD 8 billion in the coming years, driven by rising prevalence of infectious diseases, demand for rapid testing, and adoption in resource-limited settings. In the longer term, Lab On Card targets the broader PoC diagnostics market. The overall global PoC diagnostics market is forecast to reach approximately USD 80 billion in the early 2030s, reflecting sustained demand for rapid, decentralized diagnostic solutions. Within this larger market, microfluidic Lab-on-Chip technologies represent a distinct and fast-growing segment, with forecasts indicating multi-billion-dollar value by 2030. This combination of short-term infectious disease focus and long-term platform scalability provides a solid commercial opportunity for innovative miniaturized diagnostic platforms such as Lab On Card.
Development Status
Proof of concept validated on ELISA assay model on real biological samples. In development of tooling to enable scale-up manufacturing solutions.
Patent Situation
In progress Incorporating IP and Know-how from both founder companies.
Further Reading
Non-confidential project summary and additional documentation available upon request. https://laboncard.com
